DDInter1876 DDInter1676
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Trimipramine {u} (Compound) resembles {v} (Compound) Clomipramine
Trimipramine {u} (Compound) binds {v} (Gene) CYP2C9
Trimipramine {u} (Compound) upregulates {v} (Gene) SUV39H1
Trimipramine {u} (Compound) downregulates {v} (Gene) CCDC86
Trimipramine {u} (Compound) causes {v} (Side Effect) Diarrhoea
Trimipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Trimipramine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Trimipramine {u} may lead to a major life threatening interaction when taken with {v} Palonosetron
Trimipramine (Compound) resembles Clomipramine (Compound)
Trimipramine (Compound) binds CYP2C9 (Gene)
Trimipramine (Compound) upregulates SUV39H1 (Gene)
Trimipramine (Compound) downregulates CCDC86 (Gene)
Trimipramine (Compound) causes Diarrhoea (Side Effect)
Trimipramine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Trimipramine may lead to a major life threatening interaction when taken with Osimertinib
Trimipramine may lead to a major life threatening interaction when taken with Palonosetron